Tuesday, August 12, 2025 12:27:33 PM
Bionano Genomics’ new VIA 7.2 software brings artificial intelligence into everyday DNA analysis. Instead of manually checking each result step by step, labs can rely on AI to spot important genetic changes in both blood disorders and inherited conditions. The program even learns from a lab’s past interpretations to get faster and more accurate over time.
VIA 7.2 also introduces a scoring system that links DNA changes to a patient’s physical traits, enabling scientists to determine which variants truly matter. Finally, it formats all results using standard genetic naming rules so that data can be easily shared and compared across different labs.
On the data-processing side, Solve 3.8.3 has grown its library of normal genetic variations by 18 percent. This bigger control database means the software is better at catching true positives, avoiding false alarms, and seeing smaller changes in the DNA. In practical terms, researchers will spend less time double-checking results and more time focusing on discoveries.
The Stratys Compute server has received a powerful boost from upgraded GPU chips. These graphics processors let labs analyze up to twice as many cancer samples each week compared with older versions. They’ve also unlocked analysis pipelines that used to run only on slower CPU servers, so labs get faster results without changing their existing workflows.
Together, these upgrades make OGM faster, smarter, and more scalable, key improvements for any lab thinking about adding this technology.
Bionano officially announced the new Stratys Compute upgrades on August 5, 2025. These enhancements are currently being deployed to 20 early-access sites, with a full commercial launch slated for the fourth quarter of 2025.
Recent BNGO News
- Bionano to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call Webcast on March 23, 2026 • GlobeNewswire Inc. • 03/09/2026 08:05:00 PM
- Bionano Symposium 2026 Concluded with 9 Speakers Describing the Breadth of Bionano Solutions and Their Potential for Use on a Large Scale • GlobeNewswire Inc. • 02/27/2026 01:00:00 PM
- 10 Presentations on Day 3 of Bionano Symposium 2026 Showcase OGM’s Utility in Unraveling the Complex Puzzles of Constitutional Genetic Disorders • GlobeNewswire Inc. • 02/26/2026 01:00:00 PM
- 11 Presentations on Day 2 of Bionano Symposium 2026 Showcase Expanding Impact of Optical Genome Mapping Across Oncology and Cell & Gene Therapy • GlobeNewswire Inc. • 02/25/2026 01:00:00 PM
- 9 Presentations Kick Off Day 1 of the Bionano Symposium 2026 Covering Advances in Optical Genome Mapping for Hematologic Malignancies • GlobeNewswire Inc. • 02/24/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 09:31:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 09:29:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 09:28:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 09:26:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 09:25:37 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/17/2026 09:06:07 PM
- Bionano Announces Bionano Symposium 2026: Global Experts Showcase Advances and Innovation in Optical Genome Mapping • GlobeNewswire Inc. • 02/09/2026 02:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 09:19:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 09:18:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 09:17:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 09:16:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 09:14:16 PM
- Bionano Announces Publication from Sanford Burnham Prebys Medical Discovery Institute Describing use of OGM to Detect Genomic Alterations Introduced by Gene Editing Technologies • GlobeNewswire Inc. • 02/04/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 01:15:51 PM
- Bionano Reports Preliminary Fourth Quarter and Full-Year 2025 Results • GlobeNewswire Inc. • 01/12/2026 01:00:00 PM
- Bionano Recaps Advances in Optical Genome Mapping Showcased at AMP 2025 • GlobeNewswire Inc. • 12/11/2025 01:00:00 PM
- Final 2026 Clinical Lab Fee Schedule Indicates a 47% Increase in Payment Determination for the Category I CPT Code for OGM use in Hematologic Malignancies • GlobeNewswire Inc. • 12/03/2025 01:00:00 PM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
RENI Completes Due Diligence on Target Acquisition; Confirms Strong Asset Base and Operational Performance • RENI • Mar 5, 2026 10:15 AM
BlackStar Engages in Talks with U.S. Senate Banking Committee Team Covering the Digital Asset Market Clarity Act • BEGI • Mar 4, 2026 4:47 PM
